Immunoglobulin E autoantibodies in atopic dermatitis associate with Type-2 comorbidities and the atopic march.
Inge Kortekaas Krohn, Fariza Mishaal Saiema Badloe, Nadine Herrmann...
https://pubmed.ncbi.nlm.nih.gov/37489049/Actively Recruiting
Led by Universitair Ziekenhuis Brussel · Updated on 2026-01-05
500
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying how specific self-reactive antibodies called IgE autoantibodies develop in newborns, especially those at high risk for atopic dermatitis AD due to family history of asthma, hay fever, or eczema. This study aims to understand when these antibodies appear, how hereditary, lifestyle, and environmental factors influence their development, and their connection to the onset of AD during the first two years of life. The study follows a group of newborns born at the University Hospital Brussels, including 400 at high risk and 100 at low risk for AD. Researchers will collect umbilical cord blood at birth and conduct blood draws at 6, 12, and 24 months. Skin barrier function will be evaluated using non-invasive tests, and samples such as skin and stool swabs will be taken to study microbes. Questionnaires will gather environmental and lifestyle information, and disease scores will be assessed at follow-up visits. Participants will have five visits over two years a prenatal baseline visit, birth visit within 72 hours, and follow-ups at 6, 12, and 24 months. The main measurement is the presence of IgE autoantibodies at birth. Researchers will monitor the development of AD, measure IgE levels, study hereditary influences through parental blood samples, and characterize infant immune cells. This comprehensive monitoring aims to reveal factors affecting antibody development and their role in AD risk.
CONDITIONS
Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis
I
Inge Kortekaas Krohn, PhD
C
Carine Vleminckx
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Universitair Ziekenhuis Brussel
Lead Sponsor
Vrije Universiteit Brussel
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 prenatal baseline visit (in-person)
Duration - From birth to 24 months of age
Participants are monitored for the presence of self-reactive antibodies and development of atopic dermatitis through blood samples, skin measurements, questionnaires, and swabs.
1 visit within 72 hours after birth and visits at 6, 12, and 24 months of age
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Inge Kortekaas Krohn, Fariza Mishaal Saiema Badloe, Nadine Herrmann...
https://pubmed.ncbi.nlm.nih.gov/37489049/Nicolas Charles, Inge Kortekaas-Krohn, Emek Kocaturk...
https://pubmed.ncbi.nlm.nih.gov/37555488/Hafsa Belasri, Hannah De Leye, Julie Saerens...
https://pubmed.ncbi.nlm.nih.gov/42215271/Pavel Kolkhir, Sabine Altrichter, Fariza Mishaal Saiema Badloe...
https://pubmed.ncbi.nlm.nih.gov/38429523/Universitair Ziekenhuis Brussel
Lead Sponsor
Vrije Universiteit Brussel
Collaborating Sponsor